Biotech Market News
Telix to Buy Radioisotope Giant ITM for $1.65 Billion
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) said Sunday it has signed a definitive agreement to acquire ITM Isotope Technologies Munich SE, a privately held German company that makes the radioactive isotopes used in a growing class of cancer drugs called radiopharmaceuticals, or radioligand therapies. These drugs attach a radioactive isotope to a molecule that…
HUTCHMED Signs GSK Cancer Deal Worth Up to $1.3B
HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) has entered an exclusive licensing agreement with GSK plc (NYSE/LSE: GSK) covering HMPL-A830, an experimental antibody-targeted cancer therapy expected to enter clinical development during the second half of 2026. Under the September 3 agreement, HUTCHMED is set to receive US$110 million upfront when the transaction closes. The company…
TScan Cuts 75% of Workforce and Pauses Phase 3 Trial
TScan Therapeutics Inc. (Nasdaq: TCRX) is eliminating approximately 75% of its workforce and pausing further enrollment in its Phase 3 ALLOHA-2 trial because it does not have sufficient capital to complete the study. The company announced the strategic reorganization on September 2. TScan will redirect its resources toward two preclinical in-vivo T-cell receptor-engineered T-cell therapy…
Rakovina Raises C$1.99M for AI-Designed Cancer Programs
Rakovina Therapeutics Inc. (TSXV: RKV; FSE: 7JO0) has completed an upsized private placement that raised aggregate gross proceeds of C$1.991 million to support its preclinical cancer-drug pipeline. According to the August 31 financing announcement, the company issued 19.91 million units at C$0.10 each across two tranches. Each unit contained one common share and one-half warrant.…
Astellas Joins U.S. Most Favored Nation Pricing Program
Astellas Pharma Inc. (TSE: 4503) announced on August 31 that it has entered a voluntary drug pricing agreement with the U.S. government. The release itself is unusually thin on specifics, disclosing just two actions and stating plainly that additional terms are not being disclosed, so this article draws on independent reporting to explain what program…
DualityBio, Genentech Team Up on Next-Gen ADC Payloads
DualityBio Inc. (HKEX: 09606) announced on August 28 that it has entered a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates (ADCs) built on DualityBio’s proprietary DUPAC payload platform. Unlike several recent biotech licensing deals that disclosed no financial terms, this one comes with real numbers:…
What Is Insider Buying and Selling in Biotech? Reading Form 4 Filings
When a biotech company’s CEO or Chief Medical Officer buys a significant amount of company stock with their own money, it can be a meaningful signal — insiders generally have access to more detailed, real-time information about the company’s clinical and regulatory trajectory than any outside investor. But insider transaction data is nuanced, frequently misinterpreted,…
Theralase Closes C$3.6M Financing for Ruvidar Development
Theralase Technologies Inc. (TSXV: TLT; OTCQB: TLTFF) has closed a brokered private placement that raised gross proceeds of C$3.555 million, providing additional capital for its cancer and antiviral development programs. According to the August 24 announcement, Theralase issued 14,812,500 units at C$0.24 per unit. Each unit contains one common share and one warrant exercisable at…
Amplitude Therapeutics Partners With Lilly on taRNA Vaccines
Amplitude Therapeutics, a private Boston-based biotechnology company, announced on August 19 a strategic research collaboration and licensing agreement with Eli Lilly and Company (NYSE: LLY) to discover and develop vaccines using Amplitude’s trans-amplifying RNA (taRNA) platform for infectious diseases. The companies did not name the specific diseases involved, describing the initial focus only as infectious…
Inside Piramal’s $7.95M Buyout of Biologics CDMO Yapan Bio
Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) announced on August 18 that it has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based contract development and manufacturing organization (CDMO) specializing in vaccines and biologics, for aggregate cash consideration of 76 crore rupees, or roughly $7.95 million. The purchase brings…
